<!DOCTYPE html>
{% load static %}
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport"
          content="width=device-width, user-scalable=no, initial-scale=1.0, maximum-scale=1.0, minimum-scale=1.0">
    <meta http-equiv="X-UA-Compatible" content="ie=edge">
    <title>Clinical Trial</title>
    <link rel="stylesheet" href="{% static 'css/base.css' %}">
    <div class="container">
        <img src="{% static 'logo.png' %}">
        <p> User: {{ user }} </p>
    </div>
    <h1>A Phase 3 study of Drug A in patients with Diabetes mellitus</h1>
</head>
<body>
    <div class="topnav">

        <a href="{% url 'index' %}">Home</a>
        {% if perms.CT_platform.view_patients %}
            <a href="{% url 'main_page' %}">Patients List</a>
        {% endif %}
        {% if perms.CT_platform.add_patients %}
            <a href="{% url 'add_patient' %}">Add Patient</a>
        {% endif %}
        {% if perms.CT_platform.view_drug %}
            <a href="{% url 'drug_list' %}">Drug List</a>
        {% endif %}
        {% if perms.CT_platform.add_drug %}
        <a href="{% url 'add_drug' %}">Add Drug</a>
        {% endif %}
         {% if perms.CT_platform.view_treatment %}
            <a href="{% url 'study_scheme_list' %}">CT Scheme List</a>
        {% endif %}
        {% if perms.CT_platform.add_treatment %}
            <a href="{% url 'add_study_scheme' %}">Add CT Scheme</a>
        {% endif %}
        {% if perms.Accounts.view_user %}
            <a href="{% url 'userlist' %}">Users</a>
        {% endif %}
        {% if user.is_authenticated %}
            {% if perms.Accounts.add_user %}
                <a href="{% url 'register' %}"> Register</a>
            {% endif %}
            <a href="{% url 'change_password' %}"> Change Password</a>
            <a href="{% url 'logout' %}"> Logout</a>
        {% else %}
            <a href="{% url 'login' %}"> Login</a>
        {% endif %}
    </div>
    <div class="content">
        {% block template %}
            Clinical trial will include 40 diabetic patients(defined by Oral Glucose Tolerance Test (OGTT) >7,8 mmol/l)
            in total, who will be randomly assigned into 1 out of 2 therapy arms with: reference drug or
            drug candidate A. Equal number of patients (20 patients) will be randomly
            allocated into each study group. The trial will be double-blinded, meaning that the drug will
            be encrypted by random: A or B labels and kept secret for employees and patients. The study begins with
            patient registration and medical interview at day 0, and followed by 70-day-long therapy with control visits
            every 14 days. The control follow-up visit should occur at least 1 year after the last dose.
            In preclinical studies the incidence of body weight loss and eyesight worsening were reported
            as the most common adverse events, those these parameters will be investigated during check-up visits.
        {% endblock %}
    </div>
</body>
<footer>
    <div class="author">
        <p>Created by Piotr Chroscicki</p>
    </div>
    <div class="copyright">
        <p>Copyright Â© 2022 Chroscicki Studio. All rights reserved.</p>
    </div>
    <div class="date">
        <p>{{ actual_date }}</p>
    </div>
</footer>
</html>